The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a
major focus of COVID-19 research due to its clinical relevance and importance in vaccine …

The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA
encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly …

Pre-existing immunity to seasonal endemic coronaviruses could have profound
consequences for antibody responses to SARS-CoV-2, induced from natural infection or …

A successful HIV vaccine eliciting broadly neutralizing antibodies (bnAbs) must overcome
the hurdle of being able to activate naive precursor B cells encoding features within their …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

Coronavirus research has gained tremendous attention because of the COVID-19
pandemic, caused by the novel severe acute respiratory syndrome coronavirus (nCoV or …

HIV is a virus that remains a major health concern and results in an infection that has no
cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues …

INTRODUCTION It is widely believed that the development of an effective neutralizing
antibody–based HIV-1 vaccine will require consistent activation of multiple germline …

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

The poor efficacy of seasonal influenza virus vaccines is often attributed to pre-existing
immunity interfering with the persistence and maturation of vaccine-induced B cell …